Zobrazeno 1 - 10
of 521
pro vyhledávání: '"Carl Morrison"'
Autor:
Linghua Wang, Siqing Fu, Aung Naing, Funda Meric-Bernstam, Carl Morrison, Joud Hajjar, Mingxuan Xu, Anas Alshawa, Bettzy Stephen, Ying Yuan, Jordi Rodon Ahnert, Abdulrazzak Zarifa, Shrutii Sarda, Timothy Looney, Sapna P Patel, Geoffrey M Lowman, Dzifa Yawa Duose, Jeffrey M Conroy, Evan Kwiatkowski
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Background Immune checkpoint inhibitors have revolutionized cancer treatment. However, they are associated with a unique spectrum of side effects, called immune-related adverse events (irAEs), which can cause significant morbidity and quickly progres
Externí odkaz:
https://doaj.org/article/5bcceeb01b534672b53dae6a7f264aae
Autor:
Tian Zhang, Carl Morrison, Sarabjot Pabla, Jason Zhu, Matthew Zibelman, Shannon McCall, Sean T Glenn, Saby George, Yong Hee Lee, Landon C Brown, Chester Kao, Matthew K Labriola, Rajan T Gupta, Daniel J George, Laura J Tafe, Farshid Dayyani, Kunal Desai, Moshe C Ornstein, Emily Kinsey, Jennifer Tran, Konstantin H Dragnev, Mary K Nesline
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Immunotherapy combinations including ipilimumab and nivolumab are now the standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers of response are lacking to predict patients who will have a favorable or unfavorabl
Externí odkaz:
https://doaj.org/article/9b968140c98748eb94a5b6265a763e29
Autor:
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood, Sebastiano Battaglia, Saby George, Gurkamal Chatta, Igor Puzanov, Carl Morrison, Kunle Odunsi, Brahm H. Segal, Grace K. Dy, Marc S. Ernstoff, Fumito Ito
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
There is an urgent need to discover blood-based biomarkers to predict response to immune checkpoint inhibitors (ICI). Here the authors show that effective ICI therapy correlates with increased frequency of circulating CX3CR1+CD8+ T cells in preclinic
Externí odkaz:
https://doaj.org/article/5ad9763c2d134ba4b389bb215a94772a
Autor:
Timothy J Looney, Dzifa Y Duose, Geoffrey Lowman, Elizabeth Linch, Joud Hajjar, Denise Topacio-Hall, Mingxuan Xu, Jianping Zheng, Anas Alshawa, Coya Tapia, Bettzy Stephen, Linghua Wang, Funda Meric-Bernstam, Lauren Miller, Alexander Glavin, Lifeng Lin, Jing Gong, Jeffrey Conroy, Carl Morrison, Fiona Hyland, Aung Naing
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 137-143 (2019)
Background: Polymorphism within the human T-cell receptor beta variable (TRBV) gene has been proposed as a risk factor for autoimmune disease and immune-related adverse events (IRAEs) during immunotherapy. Previous efforts to evaluate TRBV polymorphi
Externí odkaz:
https://doaj.org/article/17c7bbb6d68b49a9a111a96392160be2
Autor:
Brittany L. Bunch, Yingyu Ma, Kristopher Attwood, Lauren Amable, Wei Luo, Carl Morrison, Khurshid A. Guru, Anna Woloszynska‐Read, Pamela A. Hershberger, Donald L. Trump, Candace S. Johnson
Publikováno v:
Cancer Medicine, Vol 8, Iss 5, Pp 2449-2461 (2019)
Abstract Background Vitamin D3 (VitD) deficiency is linked to increased incidence and worse survival in bladder cancer (BCa). In addition to cystectomy, patients are treated with cisplatin‐based chemotherapy, however 30%‐50% of patients do not be
Externí odkaz:
https://doaj.org/article/22ca1c97f38345faa050654f631ae09d
Autor:
Sarabjot Pabla, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jacob Hagen, Vincent Giamo, Jonathan Andreas, Felicia L. Lenzo, Wang Yirong, Grace K. Dy, Edwin Yau, Amy Early, Hongbin Chen, Wiam Bshara, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Daniele Marin, Jason Zhu, Jeff Clarke, Matthew Labriola, Shannon McCall, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Arun Singavi, Ben George, Andrew Craig MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Lynn Dressler, Mark Steciuk, Oliver Binns, Deepa Kasuganti, Neel Shah, Marc Ernstoff, Kunle Odunsi, Razelle Kurzrock, Mark Gardner, Lorenzo Galluzzi, Carl Morrison
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other
Externí odkaz:
https://doaj.org/article/4f4efc20d258452fa94c335442c051f9
Autor:
Grace K. Dy, Mary K. Nesline, Antonios Papanicolau-Sengos, Paul DePietro, Charles M. LeVea, Amy Early, Hongbin Chen, Anne Grand’Maison, Patrick Boland, Marc S. Ernstoff, Stephen Edge, Stacey Akers, Mateusz Opyrchal, Gurkamal Chatta, Kunle Odunsi, Sarabjot Pabla, Jeffrey M. Conroy, Sean T. Glenn, Hanchun T. DeFedericis, Blake Burgher, Jonathan Andreas, Vincent Giamo, Maochun Qin, Yirong Wang, Kazunori Kanehira, Felicia L. Lenzo, Peter Frederick, Shashikant Lele, Lorenzo Galluzzi, Boris Kuvshinoff, Carl Morrison
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Regulatory approval of next generation sequencing (NGS) by the FDA is advancing the use of genomic-based precision medicine for the therapeutic management of cancer as standard care. Recent FDA guidance for the classification of g
Externí odkaz:
https://doaj.org/article/5167cae0cf364fa38ba58c2973088fd1
Autor:
Jeffrey M. Conroy, Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Jason Zhu, Matthew Labriola, Daniele Marin, Shannon J. McCall, Jeffrey Clarke, Daniel J. George, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Luis de la Cruz-Merino, Arun Singavi, Ben George, Alexander C. MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Deepa Kasuganti, Neel Shah, Roger Day, Lorenzo Galluzzi, Mark Gardner, Carl Morrison
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each develope
Externí odkaz:
https://doaj.org/article/ba0a2468e04d487e8d2b8fe0e2e078e6
Autor:
Sean T. Glenn, Phillip M. Galbo, Jesse D. Luce, Kiersten Marie Miles, Prashant K. Singh, Manuel J. Glynias, Carl Morrison
Publikováno v:
Oncotarget. 14:450-461
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5227e73dc18063e1e891e0c96b9d28b
https://doi.org/10.18632/oncotarget.28429
https://doi.org/10.18632/oncotarget.28429
Publikováno v:
Case Reports in Oncological Medicine, Vol 2021 (2021)
Langerhans cell histiocytosis (LCH) is a rare disease, afflicting approximately 4.6 and 1-2 per 1 million children and adults, respectively. While LCH can involve numerous organ systems such as the lung or bone, it is uncommon for the disease to be l
Externí odkaz:
https://doaj.org/article/20d5aa622c1245e4a254819b513e6ade